ST. LUKES HOSPITAL OF DULUTH
- Type
- Teaching hospital
- Where
- DULUTH, MN
- Medicare CCN
- 240047
- Received
- $189,558 in 94 records, 2019 ($10,751 general, $178,806 research)
- Source
- CMS Open Payments search ↗
On this site
- Plan sponsor: ST. LUKES HOSPITAL OF DULUTH Fuzzy (name and state)
- Federal award recipient: ST LUKES HOSPITAL OF DULUTH Fuzzy (name and state)
- Nonprofit: ST LUKES HOSPITAL OF DULUTH Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2019 | General payment | 6 | $10,751 |
| 2019 | Research payment | 88 | $178,806 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | 6 | $52,118 | 2019 |
| CSL Behring | 18 | $37,227 | 2019 |
| Janssen Research & Development, LLC | 15 | $35,471 | 2019 |
| ABBVIE INC. | 24 | $24,279 | 2019 |
| Boston Scientific Corporation | 18 | $20,698 | 2019 |
| Bard Peripheral Vascular, Inc. | 2 | $9,209 | 2019 |
| Abbott Laboratories | 4 | $7,260 | 2019 |
| Merck Sharp & Dohme LLC | 3 | $1,250 | 2019 |
| Eli Lilly and Company | 1 | $1,000 | 2019 |
| Novartis Pharmaceuticals Corporation | 1 | $600 | 2019 |
| Stryker Corporation | 1 | $290 | 2019 |
| Linvatec Corporation | 1 | $152 | 2019 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 88 | $178,806 |
| Gift | 3 | $9,499 |
| Space rental or facility fees (teaching hospital only) | 2 | $1,100 |
| Grant | 1 | $152 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2019-12-31 | AstraZeneca Pharmaceuticals LP | $1,873 | Research payment | In-kind items and services | IMFINZI Drug, Oncology | A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/adjuvant Durvalumab for t | 2019 |
| 2019-12-31 | Stryker Corporation | $290 | Gift | In-kind items and services | PROFORM Device, PATIENT CARE - PC | 2019 | |
| 2019-12-31 | Linvatec Corporation | $152 | Grant | In-kind items and services | HALL POWER Device, ORTHOPEDIC SURGERY | 2019 | |
| 2019-12-26 | ABBVIE INC. | $250 | Research payment | Cash or cash equivalent | Rinvoq Biological, Immunology | M14-465 | 2019 |
| 2019-12-19 | CSL Behring | $500 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-12-17 | CSL Behring | $2,000 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-12-17 | CSL Behring | $500 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-12-10 | AstraZeneca Pharmaceuticals LP | $12,468 | Research payment | Cash or cash equivalent | IMFINZI Drug, Oncology | A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/adjuvant Durvalumab for t | 2019 |
| 2019-12-02 | Boston Scientific Corporation | $800 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | APPRAISE ATP | 2019 |
| 2019-11-25 | ABBVIE INC. | $2,731 | Research payment | Cash or cash equivalent | Rinvoq Biological, Immunology | M14-465 | 2019 |
| 2019-11-21 | CSL Behring | $500 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-11-19 | Janssen Research & Development, LLC | $89 | Research payment | Cash or cash equivalent | A Phase 3 study comparing daratumumab . Lenalidomide and dexamethasone (DRd) versus lenalidomide and Dexamethasone (Rd) | 2019 | |
| 2019-11-14 | AstraZeneca Pharmaceuticals LP | $17,769 | Research payment | Cash or cash equivalent | IMFINZI Drug, Oncology | A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Ste | 2019 |
| 2019-11-12 | Janssen Research & Development, LLC | $1,469 | Research payment | Cash or cash equivalent | A Phase 3 study comparing daratumumab . Lenalidomide and dexamethasone (DRd) versus lenalidomide and Dexamethasone (Rd) | 2019 | |
| 2019-11-07 | CSL Behring | $1,051 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-11-07 | CSL Behring | $50 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-10-21 | Boston Scientific Corporation | $2,780 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product | PREEMPT HF | 2019 |
| 2019-10-21 | Boston Scientific Corporation | $500 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product | PREEMPT HF | 2019 |
| 2019-10-16 | Abbott Laboratories | $1,900 | Research payment | Cash or cash equivalent | Optim ICD Device, Cardiac Arrhythmias and Heart Failure | Optim Lead Insulation Material (OPTIMUM) Registry | 2019 |
| 2019-10-15 | CSL Behring | $500 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-10-10 | CSL Behring | $285 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-10-08 | ABBVIE INC. | $500 | Research payment | Cash or cash equivalent | M14-064 | 2019 | |
| 2019-10-07 | ABBVIE INC. | $320 | Research payment | Cash or cash equivalent | Rinvoq Biological, Immunology | M14-465 | 2019 |
| 2019-10-03 | Janssen Research & Development, LLC | $200 | Research payment | Cash or cash equivalent | A Phase 3 study comparing daratumumab . Lenalidomide and dexamethasone (DRd) versus lenalidomide and Dexamethasone (Rd) | 2019 | |
| 2019-10-03 | Janssen Research & Development, LLC | $130 | Research payment | Cash or cash equivalent | A Phase 3 study comparing daratumumab . Lenalidomide and dexamethasone (DRd) versus lenalidomide and Dexamethasone (Rd) | 2019 | |
| 2019-09-17 | CSL Behring | $1,546 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-09-17 | CSL Behring | $50 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-09-16 | Boston Scientific Corporation | $500 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | APPRAISE ATP | 2019 |
| 2019-09-16 | Boston Scientific Corporation | $79 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | APPRAISE ATP | 2019 |
| 2019-09-09 | ABBVIE INC. | $150 | Research payment | Cash or cash equivalent | Rinvoq Biological, Immunology | M14-465 | 2019 |
| 2019-09-05 | CSL Behring | $350 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-08-29 | ABBVIE INC. | $3,233 | Research payment | Cash or cash equivalent | Rinvoq Biological, Immunology | M14-465 | 2019 |
| 2019-08-19 | Boston Scientific Corporation | $1,125 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product | PREEMPT HF | 2019 |
| 2019-08-19 | Boston Scientific Corporation | $250 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product | PREEMPT HF | 2019 |
| 2019-08-13 | CSL Behring | $10,745 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-08-13 | CSL Behring | $400 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-08-01 | Janssen Research & Development, LLC | $500 | Research payment | Cash or cash equivalent | A Phase 3 study comparing daratumumab . Lenalidomide and dexamethasone (DRd) versus lenalidomide and Dexamethasone (Rd) | 2019 | |
| 2019-07-31 | Abbott Laboratories | $2,800 | Research payment | Cash or cash equivalent | Optim ICD Device, Cardiac Arrhythmias and Heart Failure | Optim Lead Insulation Material (OPTIMUM) Registry | 2019 |
| 2019-07-25 | CSL Behring | $500 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-07-23 | Janssen Research & Development, LLC | $1,975 | Research payment | Cash or cash equivalent | A Phase 3 study comparing daratumumab . Lenalidomide and dexamethasone (DRd) versus lenalidomide and Dexamethasone (Rd) | 2019 | |
| 2019-07-18 | Abbott Laboratories | $500 | Research payment | Cash or cash equivalent | Optim ICD Device, Cardiac Arrhythmias and Heart Failure | Optim Lead Insulation Material (OPTIMUM) Registry | 2019 |
| 2019-07-17 | ABBVIE INC. | $250 | Research payment | Cash or cash equivalent | M14-064 | 2019 | |
| 2019-07-16 | Merck Sharp & Dohme LLC | $500 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians' Choice of Single Agent Docetaxel, P | 2019 |
| 2019-07-15 | Boston Scientific Corporation | $1,600 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product | PREEMPT HF | 2019 |
| 2019-07-03 | ABBVIE INC. | $500 | Research payment | Cash or cash equivalent | M14-064 | 2019 | |
| 2019-07-02 | Merck Sharp & Dohme LLC | $250 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians' Choice of Single Agent Docetaxel, P | 2019 |
| 2019-06-25 | Janssen Research & Development, LLC | $500 | Research payment | Cash or cash equivalent | A Phase 3 study comparing daratumumab . Lenalidomide and dexamethasone (DRd) versus lenalidomide and Dexamethasone (Rd) | 2019 | |
| 2019-06-25 | ABBVIE INC. | $500 | Research payment | Cash or cash equivalent | M14-465 | 2019 | |
| 2019-06-17 | Boston Scientific Corporation | $800 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product | PREEMPT HF | 2019 |
| 2019-06-14 | Boston Scientific Corporation | $924 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | APPRAISE ATP | 2019 |
| 2019-06-11 | Merck Sharp & Dohme LLC | $500 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians' Choice of Single Agent Docetaxel, P | 2019 |
| 2019-05-29 | ABBVIE INC. | $2,731 | Research payment | Cash or cash equivalent | M14-465 | 2019 | |
| 2019-05-28 | CSL Behring | $1,000 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-05-20 | Boston Scientific Corporation | $2,400 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product | PREEMPT HF | 2019 |
| 2019-05-16 | Janssen Research & Development, LLC | $1,429 | Research payment | Cash or cash equivalent | A Phase 3 study comparing daratumumab . Lenalidomide and dexamethasone (DRd) versus lenalidomide and Dexamethasone (Rd) | 2019 | |
| 2019-05-16 | Janssen Research & Development, LLC | $800 | Research payment | Cash or cash equivalent | A Phase 3 study comparing daratumumab . Lenalidomide and dexamethasone (DRd) versus lenalidomide and Dexamethasone (Rd) | 2019 | |
| 2019-05-16 | Janssen Research & Development, LLC | $500 | Research payment | Cash or cash equivalent | A Phase 3 study comparing daratumumab . Lenalidomide and dexamethasone (DRd) versus lenalidomide and Dexamethasone (Rd) | 2019 | |
| 2019-05-13 | ABBVIE INC. | $1,879 | Research payment | Cash or cash equivalent | M14-465 | 2019 | |
| 2019-05-13 | ABBVIE INC. | $460 | Research payment | Cash or cash equivalent | M14-465 | 2019 | |
| 2019-05-03 | ABBVIE INC. | $400 | Research payment | Cash or cash equivalent | M14-465 | 2019 | |
| 2019-05-03 | ABBVIE INC. | $250 | Research payment | Cash or cash equivalent | M14-465 | 2019 | |
| 2019-05-02 | Janssen Research & Development, LLC | $699 | Research payment | Cash or cash equivalent | A Phase 3 study comparing daratumumab . Lenalidomide and dexamethasone (DRd) versus lenalidomide and Dexamethasone (Rd) | 2019 | |
| 2019-04-30 | ABBVIE INC. | $500 | Research payment | Cash or cash equivalent | M14-465 | 2019 | |
| 2019-04-30 | ABBVIE INC. | $150 | Research payment | Cash or cash equivalent | M14-465 | 2019 | |
| 2019-04-17 | ABBVIE INC. | $500 | Research payment | Cash or cash equivalent | M14-064 | 2019 | |
| 2019-04-10 | ABBVIE INC. | $3,000 | Research payment | Cash or cash equivalent | M16-292 | 2019 | |
| 2019-04-10 | ABBVIE INC. | $500 | Research payment | Cash or cash equivalent | M16-292 | 2019 | |
| 2019-04-05 | Bard Peripheral Vascular, Inc. | $4,694 | Gift | In-kind items and services | 2019 | ||
| 2019-04-05 | Bard Peripheral Vascular, Inc. | $4,515 | Gift | In-kind items and services | 2019 | ||
| 2019-04-04 | Janssen Research & Development, LLC | $500 | Research payment | Cash or cash equivalent | A Phase 3 study comparing daratumumab . Lenalidomide and dexamethasone (DRd) versus lenalidomide and Dexamethasone (Rd) | 2019 | |
| 2019-04-01 | Boston Scientific Corporation | $800 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product | PREEMPT HF | 2019 |
| 2019-03-26 | Eli Lilly and Company | $1,000 | Research payment | Cash or cash equivalent | A RANDOMIZED PHASE 2 TRIAL OF AM0010 IN COMBINATION WITH NIVOLUMAB VS. NIVOLUMAB ALONE AS SECOND-LINE THERAPY IN SUBJECT | 2019 | |
| 2019-03-18 | Boston Scientific Corporation | $800 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product | PREEMPT HF | 2019 |
| 2019-03-18 | Boston Scientific Corporation | $79 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | APPRAISE ATP | 2019 |
| 2019-03-15 | Novartis Pharmaceuticals Corporation | $600 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | ENTRESTO Drug, CARDIOVASCULAR | 2019 | |
| 2019-03-15 | ABBVIE INC. | $500 | Research payment | Cash or cash equivalent | M14-064 | 2019 | |
| 2019-03-12 | ABBVIE INC. | $906 | Research payment | Cash or cash equivalent | Humira Biological, Immunology | M14-465 | 2019 |
| 2019-02-28 | ABBVIE INC. | $3,318 | Research payment | Cash or cash equivalent | Humira Biological, Immunology | M14-465 | 2019 |
| 2019-02-11 | AstraZeneca Pharmaceuticals LP | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | BRILINTA Drug, Cardiovascular and Metabolism | 2019 | |
| 2019-02-07 | Janssen Research & Development, LLC | $7,803 | Research payment | Cash or cash equivalent | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men With Non-Metastatic (M0) | 2019 | |
| 2019-02-04 | Boston Scientific Corporation | $510 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | APPRAISE ATP | 2019 |
| 2019-01-30 | Abbott Laboratories | $2,060 | Research payment | Cash or cash equivalent | Optim ICD Device, Cardiac Arrhythmias and Heart Failure | Optim Lead Insulation Material (OPTIMUM) Registry | 2019 |
| 2019-01-25 | ABBVIE INC. | $500 | Research payment | Cash or cash equivalent | Humira Biological, Immunology | M14-465 | 2019 |
| 2019-01-24 | Janssen Research & Development, LLC | $5,977 | Research payment | Cash or cash equivalent | A Phase 3 study comparing daratumumab . Lenalidomide and dexamethasone (DRd) versus lenalidomide and Dexamethasone (Rd) | 2019 | |
| 2019-01-22 | CSL Behring | $12,000 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-01-22 | AstraZeneca Pharmaceuticals LP | $10,770 | Research payment | Cash or cash equivalent | BRILINTA Drug, Cardiovascular and Metabolism | Upstream Ticagrelor Registry Study | 2019 |
| 2019-01-22 | Boston Scientific Corporation | $250 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product | PREEMPT HF | 2019 |
| 2019-01-17 | Janssen Research & Development, LLC | $12,900 | Research payment | Cash or cash equivalent | A Phase 3 study comparing daratumumab . Lenalidomide and dexamethasone (DRd) versus lenalidomide and Dexamethasone (Rd) | 2019 | |
| 2019-01-17 | CSL Behring | $2,750 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-01-17 | CSL Behring | $2,500 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-01-15 | AstraZeneca Pharmaceuticals LP | $8,737 | Research payment | Cash or cash equivalent | BRILINTA Drug, Cardiovascular and Metabolism | A Multinational Randomised Double Blind Placebo Controlled Trial to Evaluate the Effect of Ticagrelor 90 mg twice dai | 2019 |
| 2019-01-09 | ABBVIE INC. | $250 | Research payment | Cash or cash equivalent | Humira Biological, Immunology | M14-465 | 2019 |
| 2019-01-07 | Boston Scientific Corporation | $4,000 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product | PREEMPT HF | 2019 |
| 2019-01-07 | Boston Scientific Corporation | $2,500 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product | PREEMPT HF | 2019 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Duluth, MN, county St. Louis County, MN, state Minnesota; placed by its city name.
| Measure | Place (city or town) Duluth, MN | County St. Louis County, MN | State Minnesota |
|---|---|---|---|
| Population B01003 | 87,093 | 200,123 | 5,739,445 |
| Population, 2020 census P1 | 86,697 | 200,231 | 5,706,494 |
| Median age B01002 | 35.2 | 41.2 | 38.8 |
| Under 18 B01001 | 17.6% | 18.6% | 22.9% |
| 65 and over B01001 | 17.3% | 21.4% | 17.3% |
| Households B11001 | 37,447 | 87,115 | 2,307,955 |
| Foreign born B05002 | 3.1% | 1.9% | 8.7% |
| Median household income B19013 | $68,807 | $70,069 | $89,062 |
| Median family income B19113 | $102,608 | $95,686 | $113,993 |
| Per capita income B19301 | $41,503 | $41,302 | $48,237 |
| Poverty rate B17001 | 16.8% | 13.2% | 9.3% |
| Unemployment rate B23025 | 4.7% | 4.6% | 4.1% |
| Civilian labor force B23025 | 48,580 | 102,280 | 3,119,042 |
| Mean commute (minutes) B08013 | 17.3 | 19.9 | 22.7 |
| Bachelor's degree or higher B15003 | 44.0% | 33.6% | 39.4% |
| Housing units B25001 | 39,978 | 104,263 | 2,545,030 |
| Owner-occupied B25003 | 59.4% | 71.2% | 72.2% |
| Renters B25003 | 40.6% | 28.8% | 27.8% |
| Median home value B25077 | $242,700 | $221,400 | $329,300 |
| Median gross rent B25064 | $1,087 | $1,013 | $1,280 |
| White, not Hispanic B03002 | 86.6% | 89.5% | 75.9% |
| Black B03002 | 2.7% | 1.6% | 6.9% |
| Hispanic or Latino B03002 | 2.6% | 1.9% | 6.4% |
| Asian B03002 | 1.7% | 1.0% | 5.1% |
| American Indian and Alaska Native B03002 | 1.3% | 1.5% | 0.7% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Duluth, MN.
Comments